Results 191 to 200 of about 138,230 (307)

Global, regional, and national burden of lymphoma from 1990 to 2021: a comprehensive analysis based on the global burden of disease study 1990-2021. [PDF]

Eur J Med Res
Shi Y, Cao T, Xu Y, Liu L, Wen H, Zhao Y, Sun J, Zheng X, Jin J, Tong H, Huang Y, Xie W.   +11 more
europepmc   +1 more source

Choosing between Nivo‐AVD and BrECADD: Hodgkin lymphoma's new era

British Journal of Haematology, EarlyView.
Edward R. Scheffer Cliff, Sean McKeague, Michael J. Dickinson   +2 more
wiley   +1 more source

Diffuse CD30‐Positive Cutaneous Infiltrate in a Clinically Suspected Hidradenitis Suppurativa Lesion: Histopathologic and Diagnostic Challenges

Journal of Cutaneous Pathology, EarlyView.
ABSTRACT Hidradenitis suppurativa (HS) is a chronic inflammatory skin disorder affecting apocrine gland–bearing areas. We report a 38‐year‐old male with a lesion in the left axilla, initially clinically interpreted as HS and resistant to antibiotics.
R. Gervasi, G. L. Piazzetta, G. Soluri, C. Scigliano, C. Pelaia, V. Zuccalà, C. Gentile, N. Lobello, E. Allegra, E. Chiarella, N. Innaro   +10 more
wiley   +1 more source

Elevated lymphoma risk in patients with chronic pruritus and chronic prurigo

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and objectives Chronic pruritus (CP) and chronic prurigo (CPG, including prurigo nodularis) are prevalent, debilitating diseases with diverse comorbidities, including malignancies. This retrospective cohort study evaluated the prevalence and risk of lymphoma in CP and CPG patients, including key risk factors, and sex‐ and ancestry ...
Svenja Royeck, Henning Olbrich, Steffen Koschmieder, Claudia Zeidler, Felix Witte, Konstantin Agelopoulos, Henning Wiegmann, Michael Storck, Johannes Benedict Oehm, Ralf J. Ludwig, Sonja Ständer   +10 more
wiley   +1 more source

Disease burden of hematological malignancies worldwide, in China and in the United States based on the GLOBOCAN 2022 and Global Burden of Disease 2021 data. [PDF]

Chin Med J (Engl)
Lin M, Sun W, Huang X, Zhao X.
europepmc   +1 more source

Emerging Techniques in Minimally Invasive Surgery in Hematologic Malignancies

European Journal of Haematology, EarlyView.
ABSTRACT Hematologic malignancies represent the most common cancers in children. While the mainstays of treatment are chemotherapy and potentially hematopoietic stem cell transplant, minimally invasive surgery (MIS) has a role in the diagnosis and management of complications related both to disease and therapy as well as common pediatric surgical ...
Alejandro Chara, Katlyn G. McKay, Harold N. Lovvorn III, Joseph C. Fusco   +3 more
wiley   +1 more source

Anti-TIM-3 antibody TQB2618 in combination with penpulimab in relapsed or refractory classic Hodgkin lymphoma previously treated with PD-1/PD-L1 therapy: a multicenter, open-label, single-arm, phase Ib clinical trial. [PDF]

J Immunother Cancer
Hong H, Chen Z, Cui J, Zhang Q, Li P, Tao R, Huang H, Wang B, Li W, Wu H, Wei J, Su L, Zhang Z, Zhong M, Wang H, Wang C, Zhou H, Wang J, Dong M, Lin T.   +19 more
europepmc   +1 more source

Loncastuximab Tesirine in Relapsed/Refractory Diffuse Large B‐Cell Lymphoma: Evidence and Practical Guidance From Italian Clinical Experience

European Journal of Haematology, EarlyView.
ABSTRACT Patients with relapsed/refractory (R/R) diffuse large B‐cell lymphoma (DLBCL) who progress to the third‐line setting face a lack of standardized treatment, despite the presence of multiple available therapies. In this context, antibody–drug conjugates represent a relatively new class of anticancer agents; among them, loncastuximab tesirine is ...
Francesca Bonello, Andrea Aroldi, Alessia Castellino, Lara Mannelli, Elia Boccellato, Serena Rosati, Luisa Verga, Umberto Vitolo   +7 more
wiley   +1 more source

Adriamycin, Vinblastine and Dacarbazine With Immunotherapy Achieves Complete Metabolic Response in a Patient With Classical Hodgkin Lymphoma and Dyskeratosis Congenita. [PDF]

J Hematol
Slapnicar C, Lala P, Lee S, Zandi S, Trinkaus M.   +4 more
europepmc   +1 more source

Low Risk of Central Nervous System Relapse Among Patients With T‐Cell/Histiocyte‐Rich Large B‐Cell Lymphoma Despite High‐Risk Disease Presentation

European Journal of Haematology, EarlyView.
ABSTRACT T‐cell/histiocyte‐rich large B‐cell lymphoma (THRLBCL) is a rare subtype of large B‐cell lymphoma (LBCL) for which central nervous system (CNS) relapse remains a devastating complication. The CNS International Prognostic Index (IPI) is usually used to predict the risk of CNS relapse. However, the overall risk of CNS relapse among patients with
Atte Karhu, Sara Aronen, Aino Rönkä, Kaisa Sunela, Tuula Klaavuniemi, Annikki Aromaa‐Häyhä, Milla Kuusisto, Otto Jokelainen, Jan Böhm, Kristiina Vuolukka, Ulla‐Mari Arkko, Samuli Vaittinen, Minna Harmanen, Juha P. Väyrynen, Hanne Kuitunen, Sonja Nousiainen, Joonas Kuitunen, Juho Kangas, Eetu Pellonperä, Henri Kurttila, Miko Pietilä, Jaakko Tirkkonen, Outi Kuittinen   +22 more
wiley   +1 more source